← Back to articles

FDA Orders Vision‑Loss Warning on All GLP‑1 Weight‑Loss Drugs, Bigfoot and Yeti Accidentally Turn Hospital Pharmacy Into a “Blind‑Spot”

Updated 2026-11-10

Satire

Article coverAI Generated

The Food and Drug Administration announced Tuesday that every GLP‑1 weight‑loss medication must now carry a warning about a rare “eye‑stroke” risk. The directive, which applies to everything from injectable semaglutide to oral orforglipron, is meant to protect patients from sudden vision loss. What the FDA did not anticipate was that two very large, very furry consultants would interpret “label update” as a lucrative marketing opportunity.

On Wednesday morning, the pharmacy at St. Clement’s Medical Center was buzzing—literally. A brand‑new label‑printing line, installed just weeks earlier, had been humming along, spewing out FDA‑approved warning stickers that read:

Eye‑Stroke Warning: Non‑arteritic anterior ischemic optic neuropathy (NAION) may occur. Discontinue use and seek immediate ophthalmologic evaluation if sudden vision loss develops.

Enter Bigfoot, a shaggy, dark‑brown cryptid who recently graduated from a community college certificate program in “Creative Retail Merchandising.” He arrived on a rolling cart, backward red cap perched jauntily, a chunky gold chain glinting in the sterile fluorescent light. Beside him, Yeti—white‑fur, tinted aviator sunglasses, blue fanny pack—carried a tablet loaded with a custom spreadsheet titled “Sticker Profitability Forecast.”

“Yo, Bigfoot,” Yeti said, tapping the screen, “the FDA just gave us a free pass to rebrand these warnings as promotional offers. Look at the numbers—if we replace ‘Warning’ with ‘Deal,’ we can boost sales by at least 27 %.”

Bigfoot, who has never read a legal disclaimer in his life, responded with the kind of confidence that only comes from never having been held accountable for a mis‑print: “We’ll just slap a discount on the side. People love a good bargain, especially when it’s attached to a medical label.”

Within minutes the duo commandeered the conveyor belt. Bigfoot, perched precariously atop the moving line, began slapping oversized stickers onto every GLP‑1 vial that passed. The stickers now read:

Eye‑Stroke Warning: See the Savings!
Buy one, get one free – limited time only.

Yeti, meanwhile, had hacked the printer’s firmware to repeat the “Buy One, Get One” message on every label, regardless of the drug’s actual packaging. He leaned back, smirking, as the machine whirred louder, producing a steady stream of “discount” warnings that glittered with the same FDA‑mandated font.

The first nurse to notice the change was Jenna Morales, a veteran pharmacist with a penchant for precise documentation. She lifted a bottle of semaglutide, squinting at the bright orange sticker.

“Is this a warning or a coupon?” she muttered, then called over her colleague, Dr. Patel, an ophthalmologist who had just finished a conference on NAION.

Dr. Patel examined the label, raised an eyebrow, and replied, “If the eye‑stroke is real, the savings are not.” He turned to the pharmacy manager, who was already on a frantic call with the hospital’s legal department.

Meanwhile, in the back office, Bigfoot was already drafting a press release titled “Bigfoot’s Vision‑Saving Discounts: A Clear Path to Profit.” Yeti, never one to let a good spreadsheet go to waste, had added a column for “Projected Revenue from Mis‑labeled Stickers” that now read “$1.2 million, assuming 5 % of patients actually read the fine print.”

The situation escalated when a patient, Mr. Larkin, walked in to pick up his weekly dose of tirzepatide. He stared at the sticker, then at the pharmacist, and asked, “Does this mean I’m getting a discount on my eyesight?”

Jenna, trying to maintain composure, answered, “The discount applies to the medication, not the vision. Although, if you lose your sight, you’ll certainly save on eye‑care appointments.”

At that moment, the pharmacy’s alarm system, designed to detect temperature spikes in the medication storage area, went off. The cause? The conveyor belt had jammed, sending a cascade of mislabeled vials onto the floor, where they formed a small, glittering mountain of “Buy One, Get One Free” warnings.

Hospital security arrived, escorted the two cryptids out, and called in the FDA’s regional compliance office. When the compliance officer, a stoic woman named Ms. Greene, asked how the stickers had been altered, Yeti offered a smooth, “We were merely optimizing the label for consumer engagement. Our data suggests that a discount cue increases adherence.”

Ms. Greene, who had spent her career auditing label‑compliance, stared at the gold chain and the fanny pack. “You’ve turned a safety warning into a sales pitch,” she said. “That’s not just a violation; it’s a public health hazard.”

Bigfoot, ever the opportunist, tried to salvage the situation. “Look, we can call this a community outreach program. ‘See the Savings’ is a public‑service announcement about eye health—see more, save more.”

Yeti added, “And the ‘Buy One, Get One’ could be interpreted as a metaphor for the two eyes. One is for seeing, the other for…well, seeing the deal.”

The hospital’s legal team filed an incident report, the FDA issued a formal warning to St. Clement’s, and the pharmacy was forced to revert to the original FDA‑approved stickers. The misprinted stickers were collected, shredded, and donated to a local art school for a “post‑modern collage” project.

In the end, the FDA’s class‑wide warning remains intact, and the cryptid duo’s brief foray into pharmaceutical marketing has become a cautionary tale for both regulators and anyone who thinks a gold chain qualifies as a credential.

As the dust settled, Bigfoot turned to Yeti and said, “Well, we didn’t lose any eyes, but we definitely lost the discount.”

Yeti, adjusting his aviators, replied, “At least the patients can’t see the fine print now.”

Real-story inspiration:

fda.gov

ophthalmologytimes.com

drugdiscoverytrends.com

cnn.com

washingtonpost.com

ksdk.com

biospace.com

drugwatch.com

ophthalmologytimes.com

pharmacytimes.com

pharmacyspace.com.au

drugs.com

fda.gov

cbsnews.com

midwesteyeprofessionals.com

9news.com

mdlupdate.com

europa.eu

beckershospitalreview.com

investing.com

Explore more articles →Page views: 19